PreDxion Bio

PreDxion Bio, founded in 2017, emerged from research conducted at the University of Michigan's Pediatric Critical Care Precision Laboratory. The company was established by Walker McHugh, who has a background in immunology and medical product development from the University of Michigan, and Dr. Timothy Cornell, a physician at the same university. Caroline Landau, an MBA student at the time, was also part of the initial founding team. The venture was a participant in the Y Combinator S17 batch and has received accolades such as the University of Michigan Graduate Student Entrepreneur of the Year in 2017 for McHugh.

The firm is centered on developing precision medicine diagnostics to address dysfunctional immune responses in critically ill patients. Its core technology, spun out of the University of Michigan, is a near real-time cytokine and biomarker detection platform. This platform formed the basis for their first product, MicroKine, a diagnostic device designed to quantify multiple serum cytokines from small blood volumes in under 30 minutes, a significant speed increase compared to existing technologies. This capability enables clinicians in intensive care and emergency medicine to receive actionable data on a patient's immune function, allowing for the tailoring of treatments for conditions like sepsis, ARDS, and immune responses from cancer immunotherapies.

The company's business model involves providing these diagnostic tools to hospital providers and partnering with pharmaceutical companies. This allows for the monitoring of immune responses in clinical trials, such as for CAR-T therapy, to predict adverse events like cytokine release syndrome. PreDxion Bio has received an FDA Breakthrough Device designation for its technology. During the COVID-19 pandemic, the company also directed its efforts towards creating a rapid, scalable, saliva-based antigen test. Y Combinator's directory currently lists the company as inactive.

Keywords: precision medicine, critical care diagnostics, cytokine detection, biomarker monitoring, immune response, diagnostic device, sepsis, ARDS, CAR-T therapy, Y Combinator, University of Michigan spinoff, medical diagnostics, point-of-care testing, immunotherapy, cytokine release syndrome, personalized medicine, MicroKine, biosensor platform, critical care medicine, emergency medicine, MedTech